Arroliga, A., Balk, R., Cannon, C., Dean, N., Dellinger, P., Dennen, P., … Taylor, R. (2014). Erratum: A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Critical Care Medicine, 42(5). https://doi.org/10.1097/CCM.0000000000000348

Arroliga, A., R. Balk, C. Cannon, N. Dean, P. Dellinger, P. Dennen, J. Figueroa, et al. “Erratum: A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis.” Critical Care Medicine 42, no. 5 (January 1, 2014). https://doi.org/10.1097/CCM.0000000000000348.

Arroliga A, Balk R, Cannon C, Dean N, Dellinger P, Dennen P, et al. Erratum: A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Critical Care Medicine. 2014 Jan 1;42(5).

Arroliga, A., et al. “Erratum: A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis.” Critical Care Medicine, vol. 42, no. 5, Jan. 2014. Scopus, doi:10.1097/CCM.0000000000000348.

Arroliga A, Balk R, Cannon C, Dean N, Dellinger P, Dennen P, Figueroa J, Fletcher E, Guntupalli KK, Huang DT, Levy M, Lo T, Malik I, Margolis B, Matuschak G, Moore L, Moran GJ, Moretti E, Morris P, Panacek E, Rivers E, Schmidt G, Seneff MG, Steingrub J, Taylor R. Erratum: A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Critical Care Medicine. 2014 Jan 1;42(5).